Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MapLight TherapeuticsMPLT -8.22%14 Equity-to-Asset is 0.96 as of Mar. 2026, which is 14% above its 10-year median of 0.84. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, MapLight Therapeutics ranks better than 96.12% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
MapLight Therapeutics Equity-to-Asset Related Terms
MapLight Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for MapLight Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MPLT vs SRPT, ZYME, ABCL: Equity-to-Asset Comparison
For the Biotechnology subindustry, MapLight Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MapLight Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where MapLight Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
MapLight Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MapLight Therapeutics (MPLT) has a Equity-to-Asset of 0.96 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MapLight Therapeutics and its competitors. This is 14% above median its historical median of 0.84. Over the past decade, MapLight Therapeutics' Equity-to-Asset has ranged from 0.53 to 0.96. According to the industry distribution chart, MapLight Therapeutics ranks #55 out of 1416 companies in the Biotechnology industry, placing it in the top 3.9%.
Is MapLight Therapeutics' Equity-to-Asset too high?
MapLight Therapeutics' current Equity-to-Asset of 0.96 is 14% above median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 0.96. The Biotechnology industry median Equity-to-Asset is 0.68. MapLight Therapeutics' value of 0.96 is 41.2% above this industry median. Based on the distribution chart, MapLight Therapeutics ranks #55 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Equity-to-Asset compare to SRPT and ZYME?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #55 out of 1416 companies for Equity-to-Asset. This places MapLight Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. MapLight Therapeutics' value of 0.96 is 41.2% above this benchmark. Historically, MapLight Therapeutics' own Equity-to-Asset has ranged from 0.53 to 0.96 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.68, MapLight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MapLight Therapeutics's current Equity-to-Asset of 0.96 is 41.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MapLight Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MapLight Therapeutics's current Equity-to-Asset is 0.96, which is 14% above median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Equity-to-Asset of 0.96. The current Equity-to-Asset is 0.96, which is 14% above median its 10-year median of 0.84 and 41.2% above the Biotechnology industry median of 0.68. MapLight Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Equity-to-Asset is 0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score
Get the complete analysis for MPLT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPLT has been successfully added to your 
